Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183.

Schrecengost RS, Green CL, Zhuang Y, Keller SN, Smith RA, Maines LW, Smith CD.

J Pharmacol Exp Ther. 2018 Apr;365(1):107-116. doi: 10.1124/jpet.117.245738. Epub 2018 Feb 6.

PMID:
29434052
2.

A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.

Britten CD, Garrett-Mayer E, Chin SH, Shirai K, Ogretmen B, Bentz TA, Brisendine A, Anderton K, Cusack SL, Maines LW, Zhuang Y, Smith CD, Thomas MB.

Clin Cancer Res. 2017 Aug 15;23(16):4642-4650. doi: 10.1158/1078-0432.CCR-16-2363. Epub 2017 Apr 18.

PMID:
28420720
3.

Experimental osteoarthritis in rats is attenuated by ABC294640, a selective inhibitor of sphingosine kinase-2.

Fitzpatrick LR, Green C, Maines LW, Smith CD.

Pharmacology. 2011;87(3-4):135-43. doi: 10.1159/000323911. Epub 2011 Feb 22.

PMID:
21346391
4.

Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase.

Fitzpatrick LR, Green C, Frauenhoffer EE, French KJ, Zhuang Y, Maines LW, Upson JJ, Paul E, Donahue H, Mosher TJ, Smith CD.

Inflammopharmacology. 2011 Apr;19(2):75-87. doi: 10.1007/s10787-010-0060-6. Epub 2010 Oct 11.

PMID:
20936538
5.

Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease.

Maines LW, Fitzpatrick LR, Green CL, Zhuang Y, Smith CD.

Inflammopharmacology. 2010 Apr;18(2):73-85. doi: 10.1007/s10787-010-0032-x. Epub 2010 Feb 12.

PMID:
20151210
6.

Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.

French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, Upson JJ, Green CL, Keller SN, Smith CD.

J Pharmacol Exp Ther. 2010 Apr;333(1):129-39. doi: 10.1124/jpet.109.163444. Epub 2010 Jan 8.

7.

Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase.

Maines LW, Fitzpatrick LR, French KJ, Zhuang Y, Xia Z, Keller SN, Upson JJ, Smith CD.

Dig Dis Sci. 2008 Apr;53(4):997-1012. Epub 2007 Dec 4.

8.

Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases.

Maines LW, French KJ, Wolpert EB, Antonetti DA, Smith CD.

Invest Ophthalmol Vis Sci. 2006 Nov;47(11):5022-31.

9.
10.

Compensatory responses in the aging hippocampal serotonergic system following neurodegenerative injury with 5,7-dihydroxytryptamine.

Dugar A, Keck BJ, Maines LW, Miller S, Njai R, Lakoski JM.

Synapse. 2001 Feb;39(2):109-21.

PMID:
11180498
11.

Corticosterone regulation of serotonin transporter and 5-HT1A receptor expression in the aging brain.

Maines LW, Keck BJ, Smith JE, Lakoski JM.

Synapse. 1999 Apr;32(1):58-66.

PMID:
10188639
12.

Expression of brain Gi protein in the aging F344 rat following exposure to corticosterone.

Maines LW, Polavarapu R, Lakoski JM.

Int J Dev Neurosci. 1998 Aug;16(5):341-6.

PMID:
9829170
13.

Age-dependent loss of corticosterone modulation of central serotonin 5-HT1A receptor binding sites.

Maines LW, Keck BJ, Dugar A, Lakoski JM.

J Neurosci Res. 1998 Jul 1;53(1):86-98.

PMID:
9670995
14.

Identification of central 5-HT and 5-HT1A receptors in the turtle brain (Chrysemys picta).

Larson-Prior LJ, Bushey RM, Maines LW, Lakoski JM.

Neurosci Lett. 1996 Jul 12;212(2):79-82.

PMID:
8832643

Supplemental Content

Loading ...
Support Center